https://biospectrumindia.com/rssfeed/states/uttar%20pradesh uttar pradesh https://biospectrumindia.com/news/110/28600/blacksoil-invests-rs-110-cr-in-regency-hospital-to-support-expansion-of-specialised-healthcare-in-tier-2-markets.html https://biospectrumindia.com/news/110/28600/blacksoil-invests-rs-110-cr-in-regency-hospital-to-support-expansion-of-specialised-healthcare-in-tier-2-markets.html Tue, 06 Oct 2026 15:11:43 +0530 Regency Hospital, a leading tertiary care healthcare provider in Uttar Pradesh, has raised Rs 110 crore from BlackSoil Capital to fund its expansion and investments in new healthcare infrastructure. With over three decades of experience, Regency operates hospitals and healthcare facilities across Kanpur, Lucknow, and Gorakhpur, offering multi- and super-specialty care across oncology, nephrology, gastroenterology, cardiology, critical care and other specialities. The fundraise comes as healthcare delivery and demand for specialised care continue to grow beyond India’s major metropolitan centres. The expansion of established healthcare operators across tier-2 and tier-3 markets, along with increasing insurance and government healthcare scheme penetration, is creating greater demand for institutional capital to build and expand healthcare capacity. Commenting on the fundraise, Abhishek Kapoor, the CEO, Regency Hospital Limited said, “Regency has remained focused on expanding access to quality tertiary and super-specialty healthcare across Uttar Pradesh. The Rs 110 crore financing from BlackSoil will support our investments in new healthcare infrastructure and enable us to build further capacity in markets where the demand for specialised care continues to grow.” The platform has built exposure across hospitals, diagnostics and medical equipment distribution. BlackSoil sees a growing financing opportunity across hospitals, diagnostics, specialty healthcare operators and medical equipment businesses.   ]]> https://biospectrumindia.com/news/110/28601/himalaya-wellness-csir-cdri-join-forces-to-develop-new-therapy-for-polyendocrine-metabolic-ovarian-syndrome.html https://biospectrumindia.com/news/110/28601/himalaya-wellness-csir-cdri-join-forces-to-develop-new-therapy-for-polyendocrine-metabolic-ovarian-syndrome.html Tue, 06 Oct 2026 16:55:06 +0530 Himalaya Wellness Company has entered into a licensing agreement with the Council of Scientific and Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow, to develop a new evidence-based intervention for Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly known as Polycystic Ovary Syndrome (PCOS). The collaboration brings together CSIR-CDRI’s expertise in drug discovery and phytopharmaceutical research with Himalaya’s capabilities in herbal research and product development. The partnership aims to advance the discovery and development of a safe and effective therapy for PMOS, a complex condition that affects approximately 1 in 8 women and more than 170 million people globally. Unlike conditions that affect a single organ or pathway, PMOS involves interconnected reproductive, metabolic, and endocrine factors. This complexity can make its management challenging and underscores the need for approaches that address the condition more comprehensively. Under the agreement, a standardised herbal extract developed by CSIR-CDRI scientists, Dr T. Narender and Dr Rajesh Jha, will be advanced by Himalaya Wellness Company, for its potential application in PMOS. The company will focus on formulation development, clinical safety, and efficacy evaluation, with the broader objective of translating scientific research into a potential therapeutic option for women. The collaboration reflects the growing importance of industry-academia partnerships in translating scientific discoveries into potential healthcare applications. By combining research capabilities, such partnerships can help advance innovation while enabling specialised scientific expertise and industry development capabilities to work towards a common healthcare objective. ]]> https://biospectrumindia.com/news/110/28566/medanta-to-expand-healthcare-footprint-in-up-with-land-acquisition-in-ghaziabad-for-rs-165-8-cr.html https://biospectrumindia.com/news/110/28566/medanta-to-expand-healthcare-footprint-in-up-with-land-acquisition-in-ghaziabad-for-rs-165-8-cr.html Tue, 29 Sep 2026 14:41:59 +0530 Global Health Limited (Medanta), one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, has been allotted a land parcel measuring approximately 10,560 sq. metres at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh, by the Uttar Pradesh Housing & Development Board (UPAVP). The land parcel has been allotted for approximately Rs 165.82 crore on a freehold basis through an online auction conducted by UPAVP. The strategically located parcel has the potential to accommodate the development of a 350+ bedded hospital, subject to customary and statutory approvals and the approval of the Company’s Board of Directors. The proposed hospital is expected to further strengthen the Company’s presence in the Delhi-NCR healthcare ecosystem and provide access to high-quality tertiary and quaternary healthcare services for the rapidly growing population of Ghaziabad and the surrounding catchment areas. The proposed location at Siddharth Vihar provides an opportunity to establish a large-scale integrated healthcare facility in a strategically located and rapidly developing part of Ghaziabad. The proposed hospital could enable the company to address the growing demand for advanced medical care while leveraging its clinical expertise, brand, technology, medical talent and established healthcare ecosystem. ]]> https://biospectrumindia.com/news/110/28498/wadhwani-innovation-centre-for-life-sciences-and-medical-technologies-opens-at-iit-kanpur.html https://biospectrumindia.com/news/110/28498/wadhwani-innovation-centre-for-life-sciences-and-medical-technologies-opens-at-iit-kanpur.html Thu, 17 Sep 2026 16:13:10 +0530 The Wadhwani Innovation Centre for Life Sciences and Medical Technologies - a Centre of Excellence (CoE), has been established at the Indian Institute of Technology (IIT) Kanpur to strengthen the translation of research into products and solutions for healthcare. The Centre will receive $5 million in funding over five years to support the development, validation and commercialisation of promising innovations across life sciences, biotechnology, medical technologies, and AI-enabled healthcare services. The new Centre will support high-potential research from areas like therapeutics, regenerative medicine and drug delivery to vaccines, medical devices and diagnostics. It will also focus on emerging fields like neurodegenerative diseases, mental health, antimicrobial resistance and AI-enabled healthcare. Building on IIT Kanpur’s research strengths, the Centre will help promising ideas move from the lab to real-world healthcare applications. It will support researchers through validation, IP and regulatory processes, while helping connect them with industry for technology transfer and commercialisation. The Wadhwani–IIT Kanpur Innovation Centre is part of the Wadhwani Innovation Network (WIN), the Wadhwani Foundation’s flagship innovation initiative in India, which is building a national network of Innovation Centres to strengthen research translation and commercialisation. ]]> https://biospectrumindia.com/news/110/28493/organon-announces-grants-to-support-womens-health-in-bihar-and-up.html https://biospectrumindia.com/news/110/28493/organon-announces-grants-to-support-womens-health-in-bihar-and-up.html Wed, 16 Sep 2026 17:38:40 +0530 Organon, a global healthcare company focused on women's health, has signed an agreement sealing a shared commitment with two 2026 Her Health Grant recipients in India: Population Services International India (PSI India) and Ipas Development Foundation (IDF). The grants will support programmes addressing adolescent health and well-being in Bihar and expanding access to contraceptive choice through the private health sector in Uttar Pradesh. The Organon Her Health Grants is a global programme designed to support organisations that expand access, equity, and informed choice for women and girls, marking a significant milestone in local community efforts to strengthen women’s health initiatives.  PSI India will implement the AWESOMM_HER programme in Bihar across five districts, Purnia, Katihar, Kishanganj, Araria and Gaya, integrating nutritional support, menstrual health and hygiene education, and mental health resilience counselling into the daily lives of adolescent girls. On the other hand, Ipas Development Foundation will work across five districts of Uttar Pradesh to strengthen the private health sector's capacity to offer women a fuller range of contraceptive choices, with a focus on long-acting reversible contraceptive (LARC) methods.  Speaking on the signing of the Her Health Grants agreement, Andreas Daugaard Jørgensen, Managing Director of Organon Asia Pacific, said: “India is home to the largest adolescent populations in the world and some of the most significant unmet needs in women's health, so this is an important focus for Organon. These two programmes tackle different points in a woman's life, from the health information a teenager needs to the contraceptive choices a woman makes as an adult. Both programs can have significant impact for education, health and opportunity for the women. ]]> https://biospectrumindia.com/news/110/28421/iit-kanpur-partners-with-nobel-laureate-david-bakers-lab-for-ai-guided-drug-discovery.html https://biospectrumindia.com/news/110/28421/iit-kanpur-partners-with-nobel-laureate-david-bakers-lab-for-ai-guided-drug-discovery.html Thu, 03 Sep 2026 19:12:39 +0530 Researchers at the Indian Institute of Technology (IIT) Kanpur worked with the laboratory of Nobel Prize winner Prof. David Baker at the University of Washington to help design a new kind of small protein. These proteins can block a group of receptors called GPCRs (G protein-coupled receptors), which are present on the surface of our cells and play a part in how many modern medicines act.  The study titled “De novo design of miniproteins targeting GPCRs” has been published in the journal Nature. It shows how artificial intelligence (AI) can be used to efficiently design and find the miniproteins that attach to specific GPCRs and change how they behave.  The team designed miniproteins for several GPCRs, including two called CXCR4 and CCR5. Both are being studied as possible drug targets for cancer and for viral infections such as HIV.  IIT Kanpur also contributed to visualising how one of these designed miniproteins attaches to the CXCR4 receptor. Using a powerful imaging technique called cryo-electron microscopy at its cryo-EM facility, researchers could see exactly how the two molecules fit together and how the miniprotein affects the receptor.   The findings of the study reveal that AI-based protein design is a practical tool for drug discovery. While these specific proteins are not medicines yet, and years of further testing lie ahead before it reaches the clinic, the study offers a workable method for designing targeted, protein-based treatments for receptors that have been difficult to target with drugs.  ]]> https://biospectrumindia.com/news/110/28378/park-medi-world-invests-rs-200-cr-to-develop-550-bed-hospital-in-prayagraj.html https://biospectrumindia.com/news/110/28378/park-medi-world-invests-rs-200-cr-to-develop-550-bed-hospital-in-prayagraj.html Wed, 26 Aug 2026 13:54:20 +0530 Park Medi World Limited has been awarded a Public–Private Partnership (PPP) mandate by the Prayagraj Municipal Corporation to develop and operate a 550-bed multi-super-speciality hospital in Prayagraj, Uttar Pradesh. The project entails an investment of approximately Rs 200 crore, with the hospital expected to be constructed over two years and operated under a 45-year long-term lease. The project will also receive Rs 76.52 crore in support from the State Government towards construction, helping de-risk a significant portion of the capital outlay. The Prayagraj project forms the third pillar of Park Group's Uttar Pradesh strategy. Together with its 360-bed hospital at Agra and its upcoming 400-bed facility at Gorakhpur, Park Group's total capacity in Uttar Pradesh will reach a critical mass of 1,260 beds on completion, positioning the Group as one of the leading private healthcare providers in the State and reinforcing its long-term commitment to expanding access to high-quality tertiary care across North India. ]]> https://biospectrumindia.com/news/110/28360/mahajan-imaging-labs-opens-integrated-centre-of-excellence-in-diagnostics-in-noida.html https://biospectrumindia.com/news/110/28360/mahajan-imaging-labs-opens-integrated-centre-of-excellence-in-diagnostics-in-noida.html Sat, 22 Aug 2026 18:47:41 +0530 Mahajan Imaging & Labs has expanded its diagnostic services to Uttar Pradesh with the launch of an Integrated Centre of Excellence in Diagnostics in Noida, as early detection and timely diagnosis become increasingly important to healthcare delivery. The facility brings together advanced imaging, pathology, genomics, molecular diagnostics and personalised health assessments at one location, serving patients from Noida, western Uttar Pradesh and the Delhi NCR. The centre was inaugurated by Defence Minister of India, Rajnath Singh, who lit the ceremonial lamp along with Member of Parliament from Gautam Buddh Nagar, Dr Mahesh Sharma; former Cabinet Secretary Rajiv Gauba; Member of NITI Aayog, television anchor and journalist Rajat Sharma; MP Bansuri Swaraj; actor Sharmila Tagore and other dignitaries present at the occasion. The government has expanded the national non-communicable disease (NCD) network to 770 District NCD Clinics, 6,410 NCD clinics at Community Health Centres and 233 Cardiac Care Units, reflecting the wider shift towards earlier detection and management of disease. This shift is also increasing the importance of timely and accurate diagnostics in supporting early detection, clinical decision-making and treatment planning. The newly launched centre includes Uttar Pradesh’s first Ultra-Fast AI-powered 3T MRI scanner, the Excel 3T, along with a 160-slice CT scanner. Other imaging services include 3D-4D ultrasound, Colour Doppler, shear-wave elastography, full-field digital mammography, DEXA bone densitometry, CBCT/OPG and digital X-ray, while neurophysiology services include EEG and EMG. The centre also offers comprehensive pathology services across hematology, clinical biochemistry, microbiology, serology, immunology, histopathology and cytology, along with next-generation sequencing (NGS), molecular diagnostics, genomics and personalised health assessments.   ]]> https://biospectrumindia.com/news/110/28311/p-d-hinduja-hospital-partners-with-up-government-to-strengthen-maternal-and-adolescent-healthcare.html https://biospectrumindia.com/news/110/28311/p-d-hinduja-hospital-partners-with-up-government-to-strengthen-maternal-and-adolescent-healthcare.html Fri, 14 Aug 2026 18:12:54 +0530 P D Hinduja Hospital & Medical Research Centre and the State Transformation Commission, Government of Uttar Pradesh (STC-UP), have joined hands to strengthen maternal and adolescent healthcare across 35 districts of Uttar Pradesh (UP). The programme was launched by Brajesh Pathak Ji, Deputy Chief Minister of Uttar Pradesh and Minister, Medical Health & Family Welfare. The event was held at the Ram Prakash Gupta Maternity & Child State Referral Hospital in Lucknow, where Brajesh Pathak, Deputy Chief Minister of Uttar Pradesh and Minister, Medical Health & Family Welfare, flagged off a fully equipped Hinduja Mobile Health Unit. Supported by qualified clinical and technical teams, the unit will provide point-of-care diagnostics, counselling and referral support. STC-UP will facilitate district-level coordination, administrative approvals and access to schools and community sites, supporting the programme’s integration with the state health system. The programme will focus on two key beneficiary groups: Matrishakti, comprising pregnant and lactating women under the Mukhyamantri Matritva Suraksha Sankalp Yojna, and Yuva, covering adolescents aged 13–19 years in government and aided schools as well as community settings. Through this partnership, P. D. Hinduja Hospital and the Government of Uttar Pradesh aim to strengthen maternal and adolescent healthcare across the state, with a focus on improving access to screening, timely care and greater health awareness. ]]> https://biospectrumindia.com/news/110/28172/iit-kanpur-research-reveals-how-promising-vaccine-booster-switches-on-immune-cells.html https://biospectrumindia.com/news/110/28172/iit-kanpur-research-reveals-how-promising-vaccine-booster-switches-on-immune-cells.html Tue, 21 Jul 2026 19:03:00 +0530 Scientists at the Indian Institute of Technology (IIT) Kanpur have revealed how an experimental molecule called EP67 switches on an important receptor found on human immune cells. EP67 is a candidate "adjuvant", an ingredient added to vaccines to make them work better. The finding gives researchers the first clear, close-up view of EP67 gripping its target, and hands them a blueprint for designing safer vaccines and new immune-based treatments. When we catch a bacterial or viral infection, our immune cells release a small protein called C5a, which primes the immune system to fight back. But too much of C5a for too long leads to inflammation that is harmful and can damage healthy tissue. To prevent this, the body uses enzymes in the blood to break C5a down quickly once the threat has passed. The researchers at IIT Kanpur took a cue from this natural safety mechanism and built a stripped-down copy of C5a, a short chain of just ten amino acids named EP67, that keeps the useful part of C5a's activity but works in a gentler way. It wakes up two kinds of immune cells, dendritic cells and macrophages, which help the body build lasting protection. At the same time it barely affects neutrophils, the cells most responsible for the unwanted inflammation. This is exactly what is needed in a vaccine booster - a stronger, longer-lasting immune response without the collateral damage. The detail of knowing precisely how EP67 fits its target has helped the team to redesign it, adjust the amino acid sequence to make the molecule sturdier and better at hitting its mark. From here onwards, the next steps would be refining the formulation and dosing in pre-clinical tests. The research was supported by the Indian Council of Medical Research (ICMR), the Anusandhan National Research Foundation (ANRF), the Department of Biotechnology (DBT), and the Department of Science and Technology (DST). The high-resolution structure was determined at the National cryo-EM Facility at IIT Kanpur, set up with funding from ANRF. ]]> https://biospectrumindia.com/news/110/28127/pharmacopoeia-commission-of-india-inks-mou-with-uttar-pradesh-pharmacopoeia-council.html https://biospectrumindia.com/news/110/28127/pharmacopoeia-commission-of-india-inks-mou-with-uttar-pradesh-pharmacopoeia-council.html Wed, 15 Jul 2026 19:15:19 +0530 Taking a significant step towards promoting high-quality healthcare standards and strengthening the regulatory framework, the Pharmacopoeia Commission of India (IPC) has signed a Memorandum of Understanding (MoU) with the Uttar Pradesh Pharma Council (UPPPC).  This strategic collaboration aims to strengthen the pharmaceutical and medical device ecosystem by fostering quality standards, regulatory excellence, innovation, and capacity building. Through this partnership, IPC and UPPPC will work together for strengthening quality standards and regulatory compliance in the pharmaceutical and medical device industries; Promote awareness about Indian Drug Code, Drug Vigilance and Substance Vigilance; Organise joint training programmes, workshops and awareness campaigns for stakeholders; Promote research, innovation, and industry-academia collaboration; Support Small and Medium Enterprises (MSMEs) by providing digital tools for reporting adverse events; Enhancing patient safety through quality assurance and after-sales monitoring initiatives in the market. ]]> https://biospectrumindia.com/news/110/28083/admi-and-iit-kanpur-forge-strategic-partnership-to-propel-indias-in-vitro-diagnostics-ecosystem.html https://biospectrumindia.com/news/110/28083/admi-and-iit-kanpur-forge-strategic-partnership-to-propel-indias-in-vitro-diagnostics-ecosystem.html Wed, 08 Jul 2026 21:22:20 +0530 The Association of Diagnostics Manufacturers of India (ADMI) and the Indian Institute of Technology Kanpur (IIT-K) have enacted a landmark Memorandum of Understanding designed to accelerate innovation within the nation In Vitro Diagnostics (IVD) sector. This partnership creates a powerful conduit between academic excellence and commercial diagnostic manufacturing. Spearheaded on behalf of IITK by the National Centre for Flexible Electronics (NCFlexE), this collaboration establishes a robust framework for joint project development and the commercialisation of next-generation IVD solutions. By leveraging NCFlexE’s specialised expertise in flexible electronics and advanced biosensors, the alliance serves as a dynamic platform for technological integration. For ADMI members, this agreement provides crucial access to world-class lab-to-piloting facilities, empowering domestic enterprises to successfully scale and manufacture sophisticated diagnostic technologies. Beyond immediate collaborative research, this MoU is a strategic investment in India’s healthcare infrastructure and national development. It actively drives industry-academia synergy through the exchange of academic materials, the formulation of joint research proposals, and comprehensive capacity building. Together, ADMI and IIT Kanpur will co-develop cutting-edge technology frameworks, publish authoritative white papers, and design resource development programmes tailored to fortify India's self-reliance in medical technology. Grounded in mutual interest, this alliance marks a definitive step toward technological sovereignty, equipping India's diagnostics industry with the foundational research and strategic insights required to deliver high-quality, indigenous healthcare solutions. ]]> https://biospectrumindia.com/news/110/27990/ex-apollo-construction-head-sanjeev-gupta-leads-execution-of-dj-medicity-in-up.html https://biospectrumindia.com/news/110/27990/ex-apollo-construction-head-sanjeev-gupta-leads-execution-of-dj-medicity-in-up.html Thu, 18 Jun 2026 23:40:44 +0530 DJ Group of Institutions, a Delhi–NCR-based healthcare education network operated under the Jassar Dental Medical Education Health Foundation (JDMEHF), has announced the appointment of Sanjeev Gupta as Group Head – Construction and Planning, as it advances DJ Medicity, an integrated healthcare and education campus, with a focus on strengthening execution across clinical planning, operational efficiency, and quality benchmarks. Gupta brings over 28 years of experience in project execution, construction management, and operations across healthcare, commercial, residential, and institutional infrastructure. Prior to this, he served as Construction Head at Apollo Hospitals, where he oversaw multiple greenfield and brownfield projects across India, including planning, budgeting, and execution. His experience spans the development of large-scale, super-speciality healthcare infrastructure across leading private hospital networks such as Action Cancer Hospital, Yashoda Hospitals, Max Healthcare, and Artemis Health Institute—bringing a level of technical depth and execution rigour not typically seen in conventional medical college-led projects.In his new role, Gupta will lead construction strategy, planning, and execution across the group’s infrastructure initiatives, with a primary focus on delivering the DJ Medicity project. He will oversee end-to-end execution, including design coordination, budgeting, vendor management, and regulatory compliance, aligning project timelines with the group’s broader vision of building a world-class healthcare ecosystem in Modinagar.   ]]> https://biospectrumindia.com/news/110/27936/thyrocare-sets-up-new-diagnostic-lab-in-up-in-association-with-secondmedic.html https://biospectrumindia.com/news/110/27936/thyrocare-sets-up-new-diagnostic-lab-in-up-in-association-with-secondmedic.html Wed, 10 Jun 2026 14:56:28 +0530 Thyrocare Technologies has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh (UP), in association with SecondMedic.  The new facility was inaugurated by Rajdeep Panwar, Chief Commercial Officer, Thyrocare Technologies. Prior to this launch, Thyrocare operated three laboratories in Uttar Pradesh, located in Lucknow, Noida, and Varanasi. With the addition of Prayagraj, the company further strengthens access to diagnostic services across the state.  The new laboratory is equipped  with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised as well as routine testing requirements, offering support to ongoing and  preventive healthcare needs.  This expansion aligns with the consistent focus of Thyrocare  towards meeting the increasing demand for reliable diagnostic services in emerging markets and bolstering its network. The Prayagraj diagnostic lab further expands the presence of the company in the northern part of the country. With this launch, Thyrocare continues to expand its presence in Uttar Pradesh, with an emphasis on growing the accessibility of diagnostic services  across cities beyond the metro markets. Thyrocare remains committed to strengthening its network and bringing reliable healthcare services closer to patients. ]]> https://biospectrumindia.com/news/110/27845/amity-university-inks-moa-with-quaraxia-pharmaceuticals-to-strengthen-biotech-and-biopharma-research.html https://biospectrumindia.com/news/110/27845/amity-university-inks-moa-with-quaraxia-pharmaceuticals-to-strengthen-biotech-and-biopharma-research.html Mon, 25 May 2026 13:58:21 +0530 Amity University, Uttar Pradesh has signed a Memorandum of Agreement (MoA) with Muzaffarnagar-based Quaraxia Pharmaceuticals to promote industry-academia collaboration in the fields of biotechnology and biopharma research.  The partnership aims to foster cutting-edge research and innovation in the development of Ayurveda-inspired cosmeceutical formulations. Under this collaboration, Quaraxia Pharmaceuticals will sponsor two research projects titled “Studies on Cosmeceutical Formulation Development against Aging with Superoxide Dismutase and Protease enzymes obtained from Ayurvedic Plant Sources” and “Development and Evaluation Studies on Enzyme-Based Cosmeceutical Formulation for Eczema Management: Role of Ayurvedic Plant-Derived Superoxide dismutase and Protease enzymes.”  The projects will be jointly led by Dr Nidhee Chaudhary and Dr Maryam Sarwat, Professors from Amity Institute of Biotechnology. Addressing the gathering, Prabhat Kumar, CEO Quaraxia Pharmaceuticals, noted, “Quaraxia Pharmaceuticals is delighted to collaborate with Amity University on these innovative projects focused on the development of Ayurveda-inspired enzymatic cosmeceutical formulations using Superoxide Dismutase and Protease enzymes derived from plant sources. The projects aim to create stable and bioactive formulations with potent antioxidant, anti-aging, and anti-inflammatory properties, thereby contributing towards sustainable biocosmetic innovation for skincare and eczema management.” Speaking on the occasion, Prof. (Dr) Balvinder Shukla, Vice Chancellor Amity University Uttar Pradesh, stated, “Amity University is a research and innovation-driven institution committed to aligning research with national priorities and fostering scientific excellence. Collaborations with industry leaders such as Quaraxia Pharmaceuticals help strengthen our research ecosystem and provide students and faculty with opportunities to develop innovative and impactful solutions for society.”   ]]> https://biospectrumindia.com/news/110/27779/eye-q-strengthens-lucknow-presence-with-facility-upgrade.html https://biospectrumindia.com/news/110/27779/eye-q-strengthens-lucknow-presence-with-facility-upgrade.html Fri, 08 May 2026 14:07:23 +0530 Eye-Q Super-Speciality Eye Hospitals, one of India’s leading eye care chains, has strengthened its presence in Lucknow with the upgradation of its existing Rajajipuram centre. The upgraded facility was inaugurated with the aim of further enhancing access to advanced and affordable eye care services in the city and nearby regions.   The event was graced by Kaushal Kishore, Former Union Minister of State for Housing and Urban Affairs and former Member of Parliament, as the Chief Guest. Dr Ajay Sharma, CMD & Founder, Eye-Q Eye Hospitals, and Rajat Goel, CEO & Co-founder, Eye-Q Hospitals were also present at the inauguration ceremony. Rajeshwar Singh, MLA from Sarojini Nagar and former Joint Director of the Enforcement Directorate, attended the event as the Guest of Honour, while senior BJP leader Anjani Srivastava was present as the Special Guest.   Having served millions of patients across its network, Eye-Q continues to expand and upgrade its footprint with a focus on advanced technology, experienced specialists, and patient-centric care. The upgraded Rajajipuram centre now features enhanced retina services and advanced OCT (Optical Coherence Tomography) technology, enabling more accurate diagnosis and advanced retinal care for patients. The centre is designed to provide comprehensive eye care services under one roof, ensuring timely diagnosis and effective treatment for patients in Lucknow and surrounding areas.   To mark the occasion, Eye-Q has introduced a special inaugural offer under which complete eye check-ups will be available for just Rs 100 for a limited period. The initiative aims to encourage regular eye examinations and promote better eye health awareness among the public.   ]]> https://biospectrumindia.com/news/110/27769/government-institute-of-medical-sciences-launches-advanced-paediatric-orthopaedic-surgery-facilities-in-greater-noida.html https://biospectrumindia.com/news/110/27769/government-institute-of-medical-sciences-launches-advanced-paediatric-orthopaedic-surgery-facilities-in-greater-noida.html Thu, 07 May 2026 15:09:48 +0530 The Government Institute of Medical Sciences (GIMS), Greater Noida, with support from Healthium MedTech’s CSR initiative and implemented by Plan International India Chapter, is now fully equipped to undertake advanced paediatric orthopaedic surgeries. In a major boost to child healthcare, the institute can now treat conditions such as developmental dysplasia of the hip (DDH), clubfoot, limb deformities, fractures and complex bone disorders. With the installation of specialised equipment including the Midas Rex MR8 High Speed Electric Drill System, Paediatric Hip Plating Set, Paediatric and Small Bone Drill & Saw System, Paediatric Orthopaedic Instrument Set and a C-Arm Machine, GIMS is now ready to deliver precise, safe and age-appropriate surgical care for children. India faces a significant burden of paediatric orthopaedic conditions, with 1 to 2 percent of children born with disorders such as clubfoot, and many others developing deformities due to trauma, infections or untreated conditions. In states like Uttar Pradesh, limited access to specialised care often delays treatment, increasing the risk of complications, disability and higher costs. Addressing this gap, the strengthened infrastructure at GIMS is expected to benefit over 1,000 children annually, enabling timely interventions and reducing the need for referrals outside the region. Speaking at the launch, the Chief Guest, Dr G.N. Singh, Adviser to the Chief Minister, Uttar Pradesh said, “This initiative reflects our commitment to ensuring that every child, regardless of background, has access to quality and timely healthcare. Strengthening public health institutions through such partnerships is essential to building an inclusive and equitable healthcare system.” ]]> https://biospectrumindia.com/news/110/27717/shardacare-healthcity-establishes-greater-noidas-first-comprehensive-cancer-care-centre.html https://biospectrumindia.com/news/110/27717/shardacare-healthcity-establishes-greater-noidas-first-comprehensive-cancer-care-centre.html Fri, 24 Apr 2026 00:00:00 +0530 Reinforcing its commitment to making advanced Cancer Care more accessible and patient-centric, ShardaCare-Healthcity, the largest super speciality hospital in Greater Noida, has announced a significant strengthening of its Oncology programme, establishing Greater Noida’s first complete Cancer Care Center, with the onboarding of four senior specialists across Surgical and Medical Oncology. The expansion includes the appointment of Dr Malay Nandy as Senior Director & Head, Medical Oncology; Dr Parveen Mendiratta as Director & Unit Head, Surgical Oncology; Dr Sanjeev Kumar Tuli as Associate Director, Surgical Oncology, and Dr Ruchir Tandon as Senior Consultant, Medical Oncology. The team is supported by a highly trained nursing and clinical support staff, collectively forming a comprehensive, patient-focused oncology unit equipped to manage a wide spectrum of cancer cases. Cancer incidence is witnessing a steady rise in India, making it a major public health concern. According to GLOBOCAN 2022, the country reported over 1.46 million new cases, with a projected 12–15% increase by 2030. Cancer-related mortality remains high at over 850,000 deaths annually, largely due to late diagnosis, limited awareness, and restricted access to specialised care. In response to these challenges, ShardaCare-Healthcity’s strengthened oncology programme bridges gaps between rising case volumes and access to coordinated, high-quality care by integrating medical, surgical, and radiation oncology within a single ecosystem.The programme offers chemotherapy, immunotherapy, targeted and endocrine therapy, personalised plans, daycare and regional chemotherapy; minimally invasive, robotic and laparoscopic surgeries, organ-specific resections, and reconstructive procedures; along with advanced radiotherapy including IMRT, IGRT, VMAT, stereotactic radiosurgery, brachytherapy, and precision image-guided treatments, enabling highly targeted and effective care under one roof. ]]> https://biospectrumindia.com/news/110/27633/redcliffe-labs-divests-crysta-ivf-to-moon-care-to-strengthen-focus-on-diagnostics.html https://biospectrumindia.com/news/110/27633/redcliffe-labs-divests-crysta-ivf-to-moon-care-to-strengthen-focus-on-diagnostics.html Wed, 08 Apr 2026 00:00:00 +0530 Noida-based Redcliffe Labs has announced the strategic divestment of its fertility services business, Crysta IVF, to DElhi-based Moon Care, the healthcare arm of MMG Group. The transaction reflects Redcliffe Labs' continued focus on strengthening its diagnostics capabilities and expanding its presence in preventive and advanced diagnostic services across India. The move allows the organisation to consolidate further its efforts to deliver technology-led accessible, accurate, and affordable diagnostic solutions at scale. At the same time, Crysta IVF, which achieved EBITDA profitability at the start of FY26, is well-positioned to continue its growth journey under the dedicated leadership of Moon Care, which will further strengthen its focus on delivering specialized fertility care and expanding access to reproductive health services. Speaking on the development, Aditya Kandoi, Founder & CEO, Redcliffe Labs, said: “Our priority has always been to build a strong, accessible diagnostics ecosystem rooted in preventive healthcare - with the goal of adding healthier years to people’s lives. This divestment allows us to sharpen that focus even further."  For patients already served by Crysta IVF, the transition will be seamless, with no change to ongoing operations. The existing Crysta IVF team and leadership will continue to lead the business, working closely with Moon Care, which will provide strategic guidance and mentorship. This ensures continuity of care without disruption, while also enabling the introduction of new initiatives to further enhance patient outcomes. For Redcliffe Labs, the deal signifies a sharpened focus on the diagnostic segment. This will enable the company to accelerate expansion, increase testing volumes, and deepen its presence in preventive healthcare, driving greater impact through early detection and accessible care. Alvarez & Marsal acted as the exclusive advisor to the transaction. ]]> https://biospectrumindia.com/news/110/27545/north-indias-largest-bone-marrow-transplant-centre-opens-in-greater-noida.html https://biospectrumindia.com/news/110/27545/north-indias-largest-bone-marrow-transplant-centre-opens-in-greater-noida.html Tue, 24 Mar 2026 00:00:00 +0530 ShardaCare-Healthcity, the largest super-specialty hospital in Greater Noida, has announced the inauguration of North India’s largest Bone Marrow Transplant (BMT) Centre, marking a significant milestone in advanced tertiary care in the region. The centre was formally inaugurated by Deputy Chief Minister and Minister of Health & Family Welfare, Uttar Pradesh, Brajesh Pathak, in the presence of distinguished dignitaries, medical experts, and leadership from Sharda Group. The newly launched BMT Centre at ShardaCare-Healthcity is designed to deliver comprehensive, world-class care for patients suffering from complex hematological conditions such as leukemia, lymphoma, thalassemia, aplastic anemia, and other life-threatening blood disorders. Equipped with cutting-edge infrastructure, advanced infection-controlled units, and a multidisciplinary team of highly experienced specialists, the centre sets a new benchmark for bone marrow transplant services in North India. The centre will provide comprehensive bone marrow transplant services for both pediatric and adult patients, including matched sibling, matched unrelated donor, and haploidentical transplants. It will also offer autologous BMT for autoimmune conditions, particularly multiple sclerosis, backed by high-dose and induction therapies, targeted treatments, immunotherapies, advanced graft manipulation, and CAR-T cell therapy. Equipped with dedicated HEPA-filtered transplant units for strict infection control, the centre also offers advanced diagnostics and immunology support for accurate donor matching and close monitoring. With expertise across autologous, allogeneic, and haploidentical transplants, along with integrated critical care, oncology, and hematology services under one roof, the facility is designed to deliver safe, seamless, and patient-centric care focused on better outcomes and recovery. What distinguishes ShardaCare-Healthcity’s BMT Centre is its scale, robust clinical protocols, and ability to provide end-to-end transplant care within a single integrated ecosystem, making advanced transplant services more accessible while reducing dependence on metro cities. A large number of adults continue to remain undiagnosed or live with long-term complications due to late detection. Among children, the challenge is equally concerning, with more than one in four aged 0 to 12 years suspected of having a blood disorder being diagnosed with inherited haemoglobin diseases and over half of them are below the age of three.   ]]> https://biospectrumindia.com/news/110/27518/roche-pharma-india-signs-mou-with-niper-in-raebareli.html https://biospectrumindia.com/news/110/27518/roche-pharma-india-signs-mou-with-niper-in-raebareli.html Thu, 19 Mar 2026 00:00:00 +0530 Roche Pharma India has signed a Memorandum of Understanding (MoU) with National Institute of Pharmaceutical Education and Research (NIPER) Raebareli to foster academic–industry collaboration and strengthen pharmaceutical education and research in India.   The MoU was signed at the Department of Pharmaceuticals (DoP) in the presence of Manoj Joshi, IAS, Secretary, DoP.    Roche and NIPER Raebareli will work together to bridge the gap between academic learning and real-world industry practices, equipping students and faculty with insights into evolving pharmaceutical and regulatory landscapes.   As part of the MoU, engagements like: A certificate programme in regulatory affairs for students and industry professionals, Guest lecture series by industry experts on emerging trends in AI for pharmaceutical research, drug development and healthcare innovation, scholarship-cum-industry exposure opportunities to students at NIPER Rae Bareli through Roche’s LEAP programme, and faculty immersion programs are planned.        Officials present at the event emphasised the importance of such collaborations strengthening India’s position as a global hub for biopharmaceutical innovation. Such initiatives will help build a skilled workforce, encourage research in advanced pharmaceutical technologies for a strong and resilient healthcare system.    In February 2026, Roche Pharma had signed an MoU with NIPER Mohali to partner in the areas of curriculum design and development, student mentorship, setting up professors of practice, scholarship-cum-industry exposure opportunities to students at NIPER Mohali through Roche’s LEAP programme, and delivery of industry-relevant short-term courses aimed at making the students of NIPER-Mohali as industry-ready professionals.   ]]> https://biospectrumindia.com/news/110/27503/sarvodaya-healthcare-expands-to-1200-beds-with-acquisition-of-nayati-hospital-in-mathura.html https://biospectrumindia.com/news/110/27503/sarvodaya-healthcare-expands-to-1200-beds-with-acquisition-of-nayati-hospital-in-mathura.html Tue, 17 Mar 2026 00:00:00 +0530 In a move aimed at expanding access to advanced tertiary care in Western Uttar Pradesh, where patients often travel to Delhi-NCR for complex medical treatment, Sarvodaya Healthcare has acquired Nayati Hospital in Mathura. The acquisition has been completed through the Insolvency and Bankruptcy Code (IBC) process following approval from the National Company Law Tribunal (NCLT). With this addition, Sarvodaya Healthcare’s total capacity has expanded from 800 beds to 1200 beds across the group. The hospital will now operate under Sarvodaya Healthcare’s management with 400 beds and is expected to become fully operational by June 2026, improving access to advanced healthcare services for patients across Mathura and neighbouring districts. It will focus on key specialties, including cardiology and cardiac surgery, oncology, orthopaedics and joint replacement, neurosciences, gastroenterology, and critical care, while also working towards national quality accreditations such as NABH and NABL. The facility includes 100 ICU beds, nine modular operating theatres, advanced diagnostic services, and round-the-clock emergency and trauma care. Sarvodaya Healthcare plans to invest in medical technology upgrades, strengthen clinical infrastructure, and recruit specialist doctors as part of the hospital’s operational revival.     The hospital is also expected to generate significant employment in the region, with plans to create nearly 1000+ direct jobs over the next three to four years across clinical, nursing, paramedical, and administrative roles. As part of its broader efforts to support the regional healthcare ecosystem, Sarvodaya Healthcare also plans to organise health camps, screening initiatives, and training programmes for nurses and paramedical staff, while exploring collaborations with local doctors and healthcare centres. ]]> https://biospectrumindia.com/news/110/27488/uttar-pradesh-government-and-wadhwani-ai-advance-public-health-partnership-.html https://biospectrumindia.com/news/110/27488/uttar-pradesh-government-and-wadhwani-ai-advance-public-health-partnership-.html Sun, 15 Mar 2026 00:00:00 +0530 Building on the partnership between the Government of Uttar Pradesh and Wadhwani AI (LEHS AI Unit), the state government is now advancing the collaboration by outlining an implementation roadmap for deploying a suite of AI-powered solutions across the state’s public health programs, with scope to expand the collaboration to additional solutions in the future. The collaboration aims to embed responsible AI solutions within Uttar Pradesh’s public health systems across priority areas such as tuberculosis care and management, telemedicine, maternal and child health, eye health screening, and frontline health worker support.  During the initial phase of implementation, a key focus will be on deploying seven AI-powered solutions across key public health programs. Wadhwani AI will serve as a technical partner to the state, supporting the deployment of AI-driven tools aligned with the government’s public health priorities.  The collaboration aligns with the UP AI Mission, a three-year initiative launched by the Government of Uttar Pradesh to build a state-led artificial intelligence ecosystem and accelerate the use of AI across sectors including governance, healthcare, and agriculture. In tuberculosis care, the Cough Against TB (CATB) mobile phone-based screening application will enable frontline healthcare workers to identify individuals with presumptive pulmonary TB by analyzing cough sounds and accompanying symptoms, enabling early detection even in community settings. Complementing this effort, Vulnerability Mapping for Tuberculosis (VMTB) will use geospatial AI analytics to identify high-risk locations by analyzing TB program data alongside multiple environmental and health indicators, helping health authorities prioritize targeted interventions and active case-finding activities. The Prediction of Adverse TB Outcomes (PATO), an AI-powered risk stratification tool, will help identify patients at higher risk of adverse outcomes at the onset of TB treatment and facilitate prompt, targeted, and effective interventions that, over time, will help lower mortality rates and prevent drug-resistant TB. In telemedicine, the Clinical Decision Support System (CDSS) will enable clinicians to access structured patient information and offer AI-assisted differential diagnosis recommendations during consultations, supporting the quality and consistency of care delivery across primary healthcare settings.  The collaboration will also include the deployment of Health Vaani, a voice- and text-based knowledge assistant which will provide frontline health workers with instant access to government-approved health guidelines, enabling quicker decision-making and more consistent service delivery at the community level. To address the growing burden of diabetes-related vision complications, the partnership will also deploy MadhuNetrAI, an AI-enabled screening solution that will analyze retinal images to detect diabetic retinopathy and support early referral for specialist care, particularly in resource-constrained settings where specialist availability may be limited.  In maternal and newborn health, Shishu Maapan, an AI-powered newborn anthropometry tool, will enable frontline health workers to capture accurate newborn measurements using a smartphone during home-based newborn care visits.   ]]> https://biospectrumindia.com/news/110/27365/national-institute-of-pharmaceutical-education-and-research-in-rae-bareli-inks-mou-with-boehringer-ingelheim-india.html https://biospectrumindia.com/news/110/27365/national-institute-of-pharmaceutical-education-and-research-in-rae-bareli-inks-mou-with-boehringer-ingelheim-india.html Sat, 21 Feb 2026 00:00:00 +0530 In a bid to promote pharmaceutical education and research in India, a Memorandum of Understanding (MoU) has been signed between the Rae Bareli-based National Institute of Pharmaceutical Education and Research (NIPER) and Boehringer Ingelheim India. The MoU was signed in the presence of Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers in New Delhi. On this occasion, the second batch of AMRUTV (Alliance for Pharmaceutical Research, Innovation, Translational Research and Value Acceleration) was also launched to strengthen India's innovation ecosystem and enable conversion of research outcomes into viable pharmaceutical products and entrepreneurial ventures. AMRUTV is being implemented by the Startup Incubation and Innovation Centre (SIIC), IIT Kanpur in collaboration with NIPER. The initiative is supported by Boehringer Ingelheim India Private Limited under Corporate Social Responsibility (CSR). In his address, Manoj Joshi emphasised the role of collaborative partnerships between academia and industry in strengthening the process from research to market. He said that such initiatives are crucial for fostering domestic innovation capabilities, encouraging entrepreneurship, and ensuring wider access to affordable healthcare solutions. Under the second group, five innovators have been selected for grant support to facilitate commercialization of their research. Three projects run by faculty members have been provided financial assistance of Rs 8 lakh each while two projects run by research scholars have been supported with a grant of Rs 6 lakh each. The MoU signed between Boehringer Ingelheim India and NIPER Rae Bareli also includes the Centre of Excellence for New Drug Delivery Systems (CoE-NDDS). It establishes a framework for strengthening academic and research collaborations in areas such as pharmaceutical technologies, innovative drug delivery systems, academic exchanges, and capacity-building programs. As part of this collaboration, Boehringer Ingelheim will provide researchers and institutions with access to its opnMe® Open Science platform, enabling scientific exchange and accelerating innovation in healthcare. ]]> https://biospectrumindia.com/news/110/27275/cm-yogi-adityanath-inaugurates-uttar-pradesh-pharma-conclave-1-0-in-lucknow.html https://biospectrumindia.com/news/110/27275/cm-yogi-adityanath-inaugurates-uttar-pradesh-pharma-conclave-1-0-in-lucknow.html Tue, 03 Feb 2026 00:00:00 +0530 Chief Minister (CM) Yogi Adityanath inaugurated the global congregation of investors and entrepreneurs 'Uttar Pradesh Pharma Conclave 1.0' at Hotel Taj, Lucknow, on 3 February.   The Chief Minister said that Uttar Pradesh is working with a clear vision and strong policy framework to become a leading centre for pharmaceutical manufacturing and innovation. The 'Bulk Drug Pharma Park' being developed in Lalitpur will not be just an industrial unit, it is being developed on a hub-and-spoke model with state-of-the-art R&D facilities. Medical Device Parks, a US-FDA testing lab and world-class logistics hubs are being developed in Gautam Buddha Nagar. Through the upcoming budget session in February, steps will also be taken towards establishing a world-class pharma institute in Lucknow. New pharma parks will also be developed in Bareilly and other districts. He further said, "The Pharma Conclave is part of the resolution to establish Uttar Pradesh as a manufacturing and innovation hub in the pharma sector. The government is moving forward with full strength to promote AI, telemedicine, deep-tech, med-tech, health-tech and clinical research." During the programme, the video message of Union Minister of Health and Family Welfare JP Nadda was shared. In the message, he said, "Uttar Pradesh is emerging as a key state, strengthening India’s global leadership in the pharma and healthcare sector. Under the leadership of PM Minister Narendra Modi, UP’s role is decisive in India’s transition towards an entrepreneurship- and innovation-driven economy. 'The Bulk Drug Pharma Park' in Lalitpur, the 'Medical Device Park' in the Yamuna Expressway region and the State Pharmaceutical Policy-2023 are positioning Uttar Pradesh as a reliable manufacturing hub. With better connectivity, strong infrastructure, skilled human resources and an investor-friendly environment." He further added that UP is becoming the preferred destination for pharma investment. The policy vision of the Centre and the ground-level efforts of the Uttar Pradesh government are rapidly advancing the state towards becoming a global center for pharma and biopharma manufacturing. Representatives of the industry presented the Indian Pharmaceutical Alliance (IPA) coffee table book 'The Alchemy of Cure' to Chief Minister Yogi Adityanath. The book is a well-structured and inspiring document of India’s pharmaceutical journey, effectively portraying the story of how India became the 'Pharmacy of the World' through entrepreneurship and strong policy support. To further accelerate the growth of the pharma sector, industry representatives emphasised the need for regulatory standardisation, quality assurance, infrastructure upgradation and strengthening academic and research institutions. They also stressed increasing investments to promote research and development, clinical trials and innovation, along with reinforcing public-private partnerships and supportive policy reforms.   Image caption- Dilip Shanghvi, Managing Director of Sun Pharmaceutical Industries, Executive Council Member of IPA presenting 'The Alchemy of Cure' book to CM ]]> https://biospectrumindia.com/news/110/27166/jubilant-biosys-doubles-early-chemistry-scale-up-capacity-with-new-noida-facility.html https://biospectrumindia.com/news/110/27166/jubilant-biosys-doubles-early-chemistry-scale-up-capacity-with-new-noida-facility.html Mon, 12 Jan 2026 00:00:00 +0530 Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, and a global CRDMO operating from five sites across India and Europe, has announced the opening of a new discovery and preclinical facility at Noida, doubling its overall chemistry capacity for discovery research and scale-up projects.  The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants, meeting growing demand in particular for fee-for-service (FFS) contracts.  “We have grown rapidly over the past year, well above the wider market, by expanding our FFS offerings, which enable innovators to advance discovery projects with lower risk. With improving funding conditions, we anticipate even higher demand next year, and this new facility doubles our existing capabilities. From a client perspective, we can now provide faster discovery delivery and integrated scale-up, with projects seamlessly transferred to our GMP facilities ready for any IND filing and commercial phases” commented Giuliano Perfetti, CEO - Jubilant Biosys Limited.   The new Noida facility offers biotech and pharma partners a fully unified route from discovery to scale-up, augmenting the company’s existing Chemistry Research Innovation Centre (CRIC) in Greater Noida. Collectively, this brings the total numbers of scientists across the business to more than 1300, with the new facility adding multiple manufacturing lines and having already onboarded several new clients.  Designed to handle quantities from hundreds of grams up to 25 kg, the new small-molecule hub combines two pilot plant blocks with co-located discovery labs. It features 20,000 sqft of state-of-the-art R&D space as well as 15 reactors spanning a variety of sizes from 20L through to 250L. Significantly, the facility has been designed with a potential to be expanded multifold in future and has room to quadruple capacity as client demand grows. ]]> https://biospectrumindia.com/news/110/26958/standard-chartered-and-dr-shroffs-charity-eye-hospital-launch-new-eye-care-academy-in-vrindavan.html https://biospectrumindia.com/news/110/26958/standard-chartered-and-dr-shroffs-charity-eye-hospital-launch-new-eye-care-academy-in-vrindavan.html Fri, 21 Nov 2025 00:00:00 +0530 In a landmark step towards advancing rural eye health, Standard Chartered and Dr. Shroff’s Charity Eye Hospital (SCEH), under the Bank’s flagship initiative ‘Seeing is Believing’, have inaugurated the Standard Chartered–Shroff’s Eye Care Education Academy in Vrindavan, Mathura district, Uttar Pradesh. This new academy will expand access to quality eye care and provide education and livelihood opportunities in underserved rural communities.  Since 2014, Dr. Shroff’s Charity Eye Hospital, with support from Standard Chartered, has provided comprehensive eye care services across Mathura through a state-of-the-art eye care centre in Vrindavan and a network of vision centres and community outreach programmes. Over the last decade, over 65,000 sight-restoring surgeries have been performed, and 17 lakh beneficiaries have been reached. The Vrindavan academy represents the second phase of the partnership, following the successful rollout of the first Standard Chartered–Shroff’s Eye Care Education Academy in Delhi. It will follow a hub-and-spoke model, and will provide localised, skill-based training in eye care for ophthalmologists and paramedics, with the Delhi facility as the hub for curriculum development, mentoring, and technical support. India faces a critical shortage of trained ophthalmic professionals, and common causes of preventable blindness remain prevalent in rural areas, where access to specialised care is limited. The Vrindavan academy directly addresses this through capacity building, employment generation, and community-centric care delivery. Over the next three years, this Vrindavan academy will train over 12,000 youth in diverse eye care fields. Key deliverables include training 70 ophthalmologists, 600 mid-career ophthalmologists, and 500 allied ophthalmic paramedics, with employment opportunities post training for over 70% of the trainees – 50% of which are going to be women. About 11,000 trainees will receive benefit from short-term courses and digital learning platform aiming to enhance their skills and delivery of eye care services to the community. All programmes are accredited by the National Council of Vocational and Research Training (NCVRT), ensuring adherence to national standards in vocational healthcare education.   ]]> https://biospectrumindia.com/news/110/26573/fortis-healthcare-signs-om-agreement-with-ekana-group-for-greenfield-super-specialty-hospital-in-lucknow.html https://biospectrumindia.com/news/110/26573/fortis-healthcare-signs-om-agreement-with-ekana-group-for-greenfield-super-specialty-hospital-in-lucknow.html Thu, 21 Aug 2025 00:00:00 +0530 Fortis Healthcare has signed a collaboration agreement with Ekana Group, Lucknow for operations and management (O&M) of 550 bedded greenfield super specialty hospital to be constructed near Gomti Nagar, Lucknow by the Ekana Group. Once completed, the facility will be positioned as Centre of Excellence for tertiary care services, bringing advanced medical infrastructure and global best practices to the state capital of Uttar Pradesh. Speaking on the collaboration, Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare said, "We are delighted to partner with Ekana Group to bring a state-of-the-art tertiary healthcare facility to the heart of Lucknow. Once operational, this new 550‑bed super‑specialty hospital near Gomti Nagar will significantly enhance access to advanced medical care for the city and its surrounding regions. This collaboration marks Fortis Healthcare’s third major presence in Uttar Pradesh, joining our network hospitals in Noida and Greater Noida and underscores our steadfast commitment to expanding high‑quality healthcare across the state.” Uday Sinha, Promoter of Ekana Group, said “We are happy to join hands with one of the leading healthcare chains in India - Fortis Healthcare to develop a leading-edge tertiary care hospital, one that will significantly enhance access to advanced medical services and deliver patient care where it’s most needed.” ]]> https://biospectrumindia.com/news/110/26528/fortis-noida-acquires-medtronics-o-arm-intra-operative-x-ray-rechnology.html https://biospectrumindia.com/news/110/26528/fortis-noida-acquires-medtronics-o-arm-intra-operative-x-ray-rechnology.html Wed, 13 Aug 2025 00:00:00 +0530 In a major leap for advanced surgical care, Fortis Hospital Noida has become the first hospital in Noida to install the state-of-the-art ‘O-arm’ intra-operative X-ray system.   This breakthrough technology enables surgeons to visualise bones, implants -screws, plates, rods and catheters with high precision during surgery. Its highly enabled technological design enables the patient to be positioned within the circular scanner for a complete spine scan. This supports minimally invasive techniques, shorter operation times and significantly lower radiation exposure for both patients and medical teams. When used with neuro navigation, the system acts like a GPS inside the body and enables surgeons to place implants with 99.9 percent accuracy while reducing surgical trauma and recovery time. Smaller incisions and minimal muscle injury contribute to faster healing and a reduced risk of infection. Speaking about the new technology, Dr Rahul Gupta, Senior Director and HOD, Neuro and Spine Surgery, Fortis Hospital, Noida said, “The O-arm will greatly improve the accuracy and safety of surgeries. With advanced imaging and real time navigation, we can perform complex procedures with smaller cuts, less muscle damage, lower radiation exposure and quicker recovery time for patients. This pioneering technology significantly reduces surgery duration, lowers infection risks and enhances recovery outcomes. For patients, it means less pain, smaller scars and a quicker return to normal life. For surgeons, it offers unmatched clarity and confidence during critical procedures.” With this addition, Fortis Hospital Noida further strengthens its position as a leader in healthcare technology. Fortis Noida is already equipped with modular operation theatres, robotic surgery capabilities and high-definition imaging systems, enabling it to deliver excellent medical care to patients from across the region. ]]> https://biospectrumindia.com/news/110/26470/marengo-asia-hospitals-enters-into-strategic-clinical-partnership-with-metis-in-varanasi.html https://biospectrumindia.com/news/110/26470/marengo-asia-hospitals-enters-into-strategic-clinical-partnership-with-metis-in-varanasi.html Sat, 02 Aug 2025 00:00:00 +0530 Marengo Asia Hospitals has announced a strategic clinical partnership with Metis – The Medicity Hospital, a leading multi-specialty healthcare facility located in Varanasi. With this partnership, Marengo Asia Hospitals strengthens its presence in North Cluster and expands its network to five hospitals, with over 1,800 beds. Metis – The Medicity Hospital is a 300-bedded tertiary care hospital, strategically located along the NH2 corridor, serving as a crucial healthcare hub for patients from eastern Uttar Pradesh, western Bihar, and surrounding regions. Spread across a spacious green campus, the hospital is equipped with modular operation theaters, 24x7 emergency and critical care services, state-of-the-art diagnostics, and advanced surgical infrastructure. With this partnership, Marengo Asia Hospitals will lead the operations and management of Metis – The Medicity Hospital. The integration will bring in Marengo Asia Hospitals’ robust clinical protocols, technology-driven systems, quality governance, and outcome-based care delivery models. This collaboration is part of Marengo Asia Hospitals’ strategic vision to consolidate and grow its presence across North India, while replicating its proven success in providing high quality and accountable healthcare. This partnership is expected to significantly benefit the existing patient base at Metis – The Medicity Hospital, while also extending access to super-specialty services for people from nearby towns, villages, and districts.   ]]> https://biospectrumindia.com/news/110/26247/amity-university-joins-hands-with-and-consortium-of-accredited-healthcare-organizations-caho.html https://biospectrumindia.com/news/110/26247/amity-university-joins-hands-with-and-consortium-of-accredited-healthcare-organizations-caho.html Mon, 16 Jun 2025 00:00:00 +0530 Amity University Uttar Pradesh (AUUP), Noida Campus, has signed a Memorandum of Understanding (MoU) with the Consortium of Accredited Healthcare Organisations (CAHO), with an aim to foster a strong industry-academia partnership by leveraging collective expertise, resources, and innovations to propel breakthroughs in the healthcare sector. Dr Vijay Agarwal, President, Consortium of Accredited Healthcare Organization (CAHO), averred, “During the last few years, medical harm has increased, and 2,50,000 Americans have lost their lives due to preventive medical errors. We must work together with nutritionists, dieticians and all healthcare specialists to ensure that the best healthcare services are provided to patients. It is crucial to reach out to academic institutions such as Amity and make them agents of change. Students are young minds who will make healthcare delivery safer and by working closely with the academia, conducting webinars and organizing Faculty Development Programmes, the process will become more impactful.  We still have a long way to go but the journey has already started.” Dr Balvinder Shukla, Vice Chancellor Amity University Uttar Pradesh, stated, “This collaboration marks a pivotal step forward in advancing healthcare administration and public health in India. By bringing together CAHO's expertise in healthcare quality and accreditation with Amity University's academic competence and research capabilities, the partnership will be instrumental in developing a highly skilled workforce, equipped to address the evolving challenges in healthcare management and public health, ultimately contributing to improved patient outcomes and a more robust healthcare ecosystem across the nation.” Prof. (Dr) B.C. Das, Dean, Health and Allied Sciences, AUUP, said, “Healthcare safety is essential to protect patients, healthcare workers, and the environment from harm. Healthcare safety measures help prevent medical errors, such as medication mistakes or surgical errors. Safety protocols reduce the risk of harm to patients, including injuries, infections, and adverse reactions. The MoU will serve as a catalyst to improve healthcare safety, leading to better health outcomes and patient satisfaction.” ]]> https://biospectrumindia.com/news/110/26197/chandigarh-university-up-emerges-as-new-hub-for-pharmacy-education-in-ai-and-research.html https://biospectrumindia.com/news/110/26197/chandigarh-university-up-emerges-as-new-hub-for-pharmacy-education-in-ai-and-research.html Tue, 03 Jun 2025 00:00:00 +0530 Chandigarh University, Uttar Pradesh (UP), continues to break new ground in AI-augmented multidisciplinary education with a major milestone- its School of Pharmacy has received formal approval from the Pharmacy Council of India (PCI) for its Bachelor of Pharmacy (B. Pharma) programme. This development marks a significant step in establishing Uttar Pradesh as a forward-looking destination for pharmacy education. The curriculum is designed to balance theoretical foundations with hands-on training, ensuring that students graduate as competent and industry-ready healthcare professionals. The Pharmacy Council of India has granted formal approval to Chandigarh University, Lucknow Campus to begin offering 60 seats in the Pharmacy course from the academic session 2025. Students at the School of Pharmacy can pursue careers in diverse fields such as Clinical Research, Intellectual Property Management, Regulatory Affairs, Quality Control, and Medical Writing. The university also imparts regulatory training in Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and Good Clinical Practices (GCP), ensuring graduates are prepared to work in highly regulated environments. ]]> https://biospectrumindia.com/news/110/25888/jindal-ivf-plans-to-expand-presence-in-himachal-pradesh-and-uttar-pradesh.html https://biospectrumindia.com/news/110/25888/jindal-ivf-plans-to-expand-presence-in-himachal-pradesh-and-uttar-pradesh.html Thu, 27 Mar 2025 00:00:00 +0530 Jindal IVF, a leading name in Assisted Reproductive Technology (ART) and In Vitro Fertilization (IVF) in Northern India, is set to expand its presence in Himachal Pradesh by identifying new strategic partner centres in cities like Shimla and Solan, and in Uttar Pradesh with a centre in Saharanpur. This move strengthens its commitment to delivering world-class fertility care and making its advanced services more accessible. The expansion will add to Jindal IVF's existing associate centres, while its flagship Chandigarh centre remains the region's largest IVF facility in terms of manpower. With a current workforce of 140 skilled professionals, including a team of eminent doctors, Jindal IVF aims to enhance its clinical capabilities and patient outreach through this expansion in its presence. The institution boasts a distinguished panel of experts, ensuring top-tier medical expertise in reproductive health and fertility treatments. "Expanding our presence in Himachal Pradesh and Uttar Pradesh is a step towards bridging the gap in reproductive healthcare by reaching more individuals who need our expertise. With a larger team and enhanced clinical capabilities, we remain committed to providing cutting-edge ART services with compassion and excellence," says Dr. Sheetal Jindal, Senior Consultant and IVF-PGT expert at Jindal IVF. Jindal IVF operates through five associate centres and collaborates with nursing homes across Northern India, making advanced fertility treatments accessible to a wider population. Its prime centre in Chandigarh serves as the hub, while associate centres in Yamunanagar, Mandi, Hamirpur, and Kullu extend IVF services to underserved regions. The hospital provides comprehensive fertility treatments, including reproductive disorder management, hormonal treatments, minimally invasive surgeries, and gynaecological care. ]]> https://biospectrumindia.com/news/110/25830/alphadroid-unveils-ai-powered-robotics-to-revolutionise-healthcare-in-india.html https://biospectrumindia.com/news/110/25830/alphadroid-unveils-ai-powered-robotics-to-revolutionise-healthcare-in-india.html Thu, 13 Mar 2025 00:00:00 +0530 Noida-based startup AlphaDroid, a pioneer in AI-driven robotics, has launched its state-of-the-art solutions to transform India’s healthcare sector. Designed to enhance patient experiences, streamline hospital operations, and support healthcare professionals, AlphaDroid’s breakthrough technology was showcased at the International Patient Safety Conference 2025 (IPSC) at Bharat Mandapam recently, receiving overwhelming interest from industry leaders and prospective customers. AlphaDroid’s robotic solutions aim to redefine patient care by boosting efficiency, safety, and overall service quality. The strong industry response highlights growing confidence in AI-powered innovations to modernize healthcare delivery.  Speaking at the launch, Sanjeev Kumar, Founder & CEO of AlphaDroid, stated: “Healthcare is about people—caregivers, patients, and doctors. Our mission is to empower medical professionals with next-generation technology, allowing them to focus on patient well-being. The enthusiasm from industry leaders confirms that the future of smart hospitals is here, and we are ready to lead this transformation across India.” As India rapidly embraces AI and automation, AlphaDroid is at the forefront of this shift, delivering intelligent and connected healthcare solutions. By integrating automation, hospitals can optimise efficiency, improve patient safety, and ease the burden on medical staff, paving the way for a more sustainable and patient-centric healthcare ecosystem. ]]> https://biospectrumindia.com/news/110/25819/indira-ivf-expands-into-maternity-child-healthcare-with-launch-of-matcare-in-varanasi.html https://biospectrumindia.com/news/110/25819/indira-ivf-expands-into-maternity-child-healthcare-with-launch-of-matcare-in-varanasi.html Tue, 11 Mar 2025 00:00:00 +0530 Indira IVF has announced its foray into maternity and child healthcare with the launch of MatCare Maternity & Child Hospital in Varanasi. This marks an expansion within the core offering of reproductive care, highlighting Indira IVF’s commitment to providing high-quality, integrated services that comprehensively address the needs of families. The hospital is designed to provide expertise, advanced infrastructure, critical neonatal care (Level III NICU), and personalized care under one roof for expectant mothers, new-borns, and high-risk pregnancies. With the launch of its first hospital in Varanasi, Matcare Wellness Private Limited - a wholly owned subsidiary of Indira IVF Hospital Limited expands functioning in mother & child healthcare. Equipped with advanced delivery rooms, modern operating theatres, and a Level III Neonatal Intensive Care Unit (NICU), MatCare is designed to provide seamless, end-to-end care from pregnancy to childbirth and beyond. Additionally, the facility will offer high-risk pregnancy management, minimally invasive gynaecological surgeries, neonatal surgical interventions, foetal medicine services, and postnatal rehabilitation, ensuring that mothers and new-borns receive comprehensive, expert-led medical attention. The hospital has been designed to provide high-quality treatment and critical care, offering 24/7 laboratory services, an in-house pharmacy, physiotherapy, lactation counselling, and a neonatal retrieval transport system, reinforcing its commitment to seamless, patient-centric care. MatCare Maternity & Child Hospital aims to bridge critical gaps in maternity and neonatal healthcare, making high-quality, specialized care more accessible to families across India. By prioritizing Tier 2 and Tier 3 cities, where access to advanced maternal and neonatal services remains largely unmet, MatCare brings medical expertise and infrastructure to these regions, providing more families with the care they deserve. ]]> https://biospectrumindia.com/news/110/25802/sharda-group-launches-state-of-the-art-facility-with-smart-infrastructure-in-greater-noida.html https://biospectrumindia.com/news/110/25802/sharda-group-launches-state-of-the-art-facility-with-smart-infrastructure-in-greater-noida.html Sun, 09 Mar 2025 00:00:00 +0530 Building on its legacy of excellence in healthcare and education, Sharda Group has launched Sharda Care - Healthcity, a state-of-the-art, 600+ bedded super-specialty hospital in Greater Noida. The hospital was inaugurated by Chief Minister of Uttar Pradesh, Yogi Adityanath Ji, marking a significant step in advancing high-quality healthcare for patients. During the inauguration, the Chief Minister emphasised the importance of strengthening healthcare infrastructure and making world-class medical facilities accessible to people across the country. Spread across 65 acres, Sharda Care – Healthcity has a smart JCI compliant infrastructure designed to provide comprehensive, patient-centric medical care across super-specialties, including oncology, neurosciences, orthopaedics, and cardiac science. Equipped with 160+ ICU beds, 24 modular operation theatres, and largest Level 1 Emergency & Trauma Care centre (60-beds) in the country, established in collaboration with SingHealth Singapore. The hospital houses patient driven approach, advanced diagnostics, minimally invasive surgical procedures, and precision-driven treatment pathways, ensuring early detection, advanced treatment, and seamless patient management.   ]]> https://biospectrumindia.com/news/110/25519/chandigarh-university-announces-establishment-of-ai-enabled-futuristic-campus-in-lucknow-.html https://biospectrumindia.com/news/110/25519/chandigarh-university-announces-establishment-of-ai-enabled-futuristic-campus-in-lucknow-.html Wed, 08 Jan 2025 00:00:00 +0530 Chandigarh University (CU) has announced the establishment of the first-of-its-kind Artificial Intelligence (AI) enabled next-gen futuristic campus at Unnao in Lucknow State Capital Region (SCR) of Uttar Pradesh, to provide AI-augmented multidisciplinary education tailored to the evolving needs of 21st-century learners. The AI-augmented Chandigarh University Uttar Pradesh Campus at India's first AI City in Lucknow SCR will revolutionise the country's educational landscape, with 43 AI-augmented futuristic undergraduate and postgraduate programmes. By embracing a multidisciplinary education model enriched by AI integration, these programmes will be offered across six streams, including Engineering, Business Administration, Health and Life Sciences, Humanities, Liberal Arts and Legal Studies from the 2025-26 academic year. The Uttar Pradesh government had earlier issued an 'Authorisation Letter' to Chandigarh University for its AI-integrated campus at Unnao in Lucknow SCR.  Uttar Pradesh Higher Education Minister Yogendra Upadhyay said, "Uttar Pradesh is on track to become a $1 trillion economy within the next five years as the state's GDP is projected to reach Rs 32 lakh crore by March 2025, positioning it as the fastest-growing economy in India and creating employment opportunities for 1.5 crore youth. In the past seven years, the state's economy, GDP, and per capita income have more than doubled due to the double engine government." ]]> https://biospectrumindia.com/news/110/25513/consint-ai-raises-rs-5-cr-in-seed-round-led-by-equanimity-ventures-seafund.html https://biospectrumindia.com/news/110/25513/consint-ai-raises-rs-5-cr-in-seed-round-led-by-equanimity-ventures-seafund.html Mon, 06 Jan 2025 00:00:00 +0530 GenAI driven healthcare Insurance fraud and risk management company Consint.AI has raised Rs 5 crore in a seed round led by Equanimity Ventures and Seafund. The capital raised will be deployed to scale operations through expanded sales outreach and accelerate the development of Generative AI Feature Suite for Health AI Platform. This includes enhancing fraud detection, optimising claims processing, and delivering personalised clinical care to drive innovation in healthcare. Funding raised in the current round will also support team expansion, infrastructure upgrades, and R&D efforts to strengthen its position as a leader in the health tech solutions market. Founded in 2020, Noida-based startup Consint.AI has achieved remarkable traction, expanding into India, the Middle East, and Africa. The company has recently launched CIPHR.ai, an AI-driven platform tailored for hospitals, built upon custom Generative AI models to revolutionise care personalisation in critical patient management. CIPHR.ai provides intelligence at point of care and generates claims transactions enhancing efficiency for healthcare providers. Targeted at emerging health markets and the US Accountable Care Organization (ACO) sector, this platform leverages Generative AI to address the evolving needs of modern healthcare systems In the last two quarters, the company has achieved significant growth, securing Rs 10+ crore in signed contracts. This includes multiple multi-year agreements with leading insurance providers and hospital systems, highlighting strong market validation and growing demand for its innovative solutions, particularly in the areas of Generative AI and Document Forensics. ]]> https://biospectrumindia.com/news/110/25376/samsung-rd-institute-noida-and-iit-bombay-sign-mou-to-pioneer-research-in-digital-health-ai.html https://biospectrumindia.com/news/110/25376/samsung-rd-institute-noida-and-iit-bombay-sign-mou-to-pioneer-research-in-digital-health-ai.html Thu, 21 Nov 2024 00:00:00 +0530 Samsung R&D Institute, Noida (SRI-Noida), has strengthened its commitment to industry-academia collaboration by signing a Memorandum of Understanding (MoU) with the Indian Institute of Technology Bombay (IIT Bombay). Under this MoU, SRI-Noida and IIT Bombay will explore breakthroughs in artificial intelligence (AI), digital health, and other critical areas. The five-year partnership will facilitate joint research projects, providing IIT Bombay students and faculty an opportunity to collaborate with Samsung engineers. This approach will not only open newer avenues for the students, but will enhance their industry readiness. In addition, it will equip Samsung engineers with specialized training and certification programmes from IIT Bombay in emerging technologies such as digital health and AI. The MoU was formally signed by Kyungyun Roo, Managing Director of SRI-Noida, and Prof. Upendra V. Bhandarkar, Associate Dean of Research and Development at IIT Bombay. The event, which took place at IIT Bombay, was attended by faculty members from the Koita Centre for Digital Health (KCDH), including Prof. Ranjith Padinhateeri, Head of KCDH, Prof. Nirmal Punjabi and Dr Raghavendran Lakshminarayanan.  The MoU encourages the publication of joint research papers, promoting knowledge sharing that will drive technological progress and industry-aligned innovation. Through this partnership, Samsung and IIT Bombay are setting the foundation for a sustained exchange of expertise that will push the boundaries of next-generation technologies and inspire future breakthroughs. ]]> https://biospectrumindia.com/views/110/24828/gims-will-play-a-pivotal-role-in-providing-solutions-for-validation-and-trials-for-medtech-startups-in-uttar-pradesh.html https://biospectrumindia.com/views/110/24828/gims-will-play-a-pivotal-role-in-providing-solutions-for-validation-and-trials-for-medtech-startups-in-uttar-pradesh.html Sun, 30 Jun 2024 00:00:00 +0530 GIMS Startup Centre for Medical Innovation is a public hospital-based incubator and the first-of-its-kind in UP. What was the objective of setting up this Centre?  The GIMS Startup Centre for Medical Innovation was established with the primary goal of addressing a significant challenge in India's healthcare sector: the heavy reliance on imported medical devices and the validation hurdles faced by domestically manufactured devices.  As the first public hospital-based incubator of its kind in Uttar Pradesh, our centre leverages the expertise and resources of a 630-bed hospital that serves over 50,000 patients every month. This unique setup allows us to bridge a crucial gap in the medical device development ecosystem.  Prior to the establishment of our centre, there was a noticeable disconnect between the end users of medical devices, primarily doctors and the innovators developing these technologies. Our incubator addresses this by enabling doctors to initially validate problem statements, ensuring that the solutions developed are practical and effective. The GIMS Incubation Centre offers comprehensive clinical mentoring for startups through our Startup Clinic, which is accessible to anyone by appointment. Our focus is on fostering innovation in healthcare technology, particularly in rapidly advancing fields such as artificial intelligence and machine learning. By developing affordable and cutting-edge technologies, we aim to bring all stakeholders to the table, creating a collaborative environment for innovation. We are currently in discussions with several IITs across the country to establish MoUs for clinical support, reinforcing our strength in clinical trials and efficacy testing. Our ultimate vision is to create medical technologies in India that can serve the world, with doctors incubating their research ideas into market-ready products.  Inaugurated by the Director General of Health Services, Government of India, our centre also holds the distinction of being a Stanford University Biodesign Centre in India.  We currently support 30 startups, primarily focused on medical devices. One of our standout startups, MATRI, which is developing a menstrual pain management device, has even progressed to the current season of Shark Tank, showcasing the potential and impact of our incubation efforts.   What are the unique features of this incubation centre and how will it foster research and medical innovations in the state of UP?  Our mission is to address the significant challenge of India's reliance on imported medical devices and the difficulties faced by domestically manufactured devices in the validation process. By providing a platform where doctors and innovators can work together, we aim to develop solutions that are both innovative and practically applicable, ultimately enhancing healthcare delivery in Uttar Pradesh and beyond.    What kind of infrastructure currently the incubation centre is having?  GIMS has allocated 15,000 square feet of space on the 4th floor of the hospital exclusively for the incubation centre. This comprehensive setup ensures that startups have access to all necessary resources in one location. An entire floor is dedicated to mentoring, with our expert faculty available during working hours to provide guidance and support. This ensures that startups have continuous access to clinical and technical expertise. A fully equipped clinical trial unit is available, enabling startups to conduct essential clinical trials and validate their products under real-world conditions. The facility includes two meeting rooms and a conference room, providing spaces for collaborative discussions, presentations, and strategy sessions. Also, there are co-working setups available for 30 startups, fostering a collaborative and dynamic environment. We support both physical and virtual incubation, with a physical capacity for 30 startups and the ability to mentor 100 startups virtually.  Our research wing is a standout feature, equipped with advanced facilities such as genome sequencing, BSL-2 and BSL-3 VRDL (Viral Research and Diagnostic Laboratories), and a molecular research lab. These state-of-the-art resources enable high-level biomedical research and development. We have a world-class skill lab that provides practical training and development opportunities, ensuring that startups can build and refine their technologies with hands-on experience.  Our hospital and laboratories are accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH) and the National Accreditation Board for Testing and Calibration Laboratories (NABL). This ensures that startups have access to facilities that meet the highest standards of quality and reliability.   Startups require funding at every stage. How does GIMS plans to financially support its incubatees?  GIMS has developed a comprehensive plan to financially support its incubatees, ensuring they have access to necessary resources at various stages of their development. Here’s how GIMS facilitates funding and support for its startups: GIMS has several venture capitalists (VCs) on its panel who act as mentors at the incubation centre. These VCs assist in screening startups and provide funding at different stages based on the startups’ portfolios. Their involvement ensures that startups receive not only financial support but also strategic guidance tailored to their growth needs. Startups at GIMS have access to several grants aimed at different aspects of their development. These include grants for sustenance, prototype development, marketing, conferences, and more. This broad spectrum of funding opportunities helps startups navigate the financial challenges of early-stage development. Most importantly, startups with a registered address in Uttar Pradesh are eligible for specific grants. However, GIMS also accommodates startups from other regions, ensuring they receive necessary support through the incubation programme. GIMS is a member of various associations such as ISBA (Indian Science and Technology Entrepreneurs Parks and Business Incubators Association), which helps in networking and provides access to funding platforms. This membership broadens the funding and support network available to GIMS startups. Out of 15 startups, 9 have been selected for the Stanford University Biodesign programme, which offers mentoring and prepares them for funding opportunities. GIMS startups are part of a funding programme run by Delhi Ecosystem, ISBA, KPMG, and SIDBI. Currently, 10 GIMS startups are participating in this programme, with 3 reaching the final round. This programme provides critical financial support and enhances the visibility of startups to potential investors. GIMS employs a co-incubation model where other institutions provide additional funds to GIMS startups. For instance, IIT Mandi funded a GIMS startup through the NIDHI PRAYAS programme. This approach has resulted in 30 per cent of GIMS startups receiving funding or grants through collaborative efforts. Also, GIMS assists other incubation centres in validating their startups’ devices, reinforcing its role in the broader medical innovation ecosystem. This cross-incubation support helps in building a robust network of validated and market-ready medical devices. GIMS has submitted a proposal for the BioNEST fund from BIRAC, which includes plans for a cleanroom facility, a bio-bank, and a prototype facility for startups. This proposal aims to further enhance the infrastructure and resources available to GIMS startups. Many private institutions are joining hands with GIMS, contributing to the funding and support ecosystem. These partnerships expand the financial and developmental resources available to startups. By leveraging these diverse funding sources and collaborative models, GIMS ensures that its startups receive comprehensive financial support and mentoring, enabling them to thrive and innovate in the competitive healthcare sector.   Has the centre planned to focus on a particular disease for R&D and innovation?  Yes, the GIMS Startup Centre for Medical Innovation has strategically planned to focus on specific diseases for R&D and innovation, with a particular emphasis on disease prevention.  We are actively inviting applications from across India to leverage technology for the prevention of various diseases. This initiative aligns with our broader vision of utilising advanced technology to improve public health outcomes and reduce the incidence of preventable diseases. We partnered with the Netherlands-based foundation NLR (No Leprosy Remains) on June 11, to launch a dedicated startup cohort focused on early detection and management of leprosy. This collaboration aims to develop and implement technologies that can significantly improve the early diagnosis and effective treatment of leprosy, ultimately striving towards the eradication of this disease. We are initiating a dedicated cohort to address menstrual hygiene, recognising the critical need for innovation in this area to improve women’s health and well-being. Another focus area is non-communicable diseases (NCDs). By developing point-of-care (PoC) diagnostics and other innovative solutions, we aim to enhance the management and prevention of NCDs, which are a major health challenge globally. Our vision also includes the development of advanced PoC diagnostic tools. These tools are crucial for early disease detection, timely intervention, and effective disease management, particularly in resource-limited settings. The disease prevention cohort is already live, and we have received 25 applications to date. This enthusiastic response indicates a strong interest and need for innovative solutions in disease prevention.   Mentorship is key to the development of successful startups. How is GIMS planning to leverage its in-house medical fraternity to mentor the incubatees? Will there be external mentorship collaborations?  GIMS Centre for Medical Innovation has developed a robust mentorship framework to ensure the successful development of its incubated startups.  Our clinical mentors include experienced clinicians from GIMS, encompassing both academic and hospital settings. These mentors provide invaluable insights into the practical and clinical aspects of healthcare innovation. GIMS has also collaborated with clinicians from other institutions, both public and private. This diverse pool includes clinical researchers who offer expertise in various medical fields, ensuring that startups receive well-rounded guidance on medical and clinical validation. Industry mentors include venture capitalists who provide financial insights and support, helping startups navigate the complexities of fundraising and financial management. We have experts in management and technology who mentor startups on business strategy, technological development, and market positioning, ensuring that they are well-prepared to succeed in the competitive healthcare market. Our Incubation Heads and CEOs bring a wealth of experience in startup incubation and ecosystem development. They offer strategic advice and help startups integrate into the broader innovation ecosystem. Global mentors from Stanford University Biodesign team provide world-class guidance, helping startups achieve international standards and preparing them for global markets. A major advantage comes from the in-house medical fraternity at GIMS who offer readily accessible expertise, enabling continuous and immediate support for the startups. This close proximity ensures that startups can rapidly iterate on their ideas with direct input from practicing medical professionals. GIMS serves as a validation and trial hub, leveraging its clinical mentors to facilitate rigorous testing and validation of medical devices and technologies. This capability is crucial for startups to prove the efficacy and safety of their innovations.   What is the long-term road map of GIMS incubation centre? Adjacent to the Yamuna Expressway, UP government is establishing one of the largest medical device parks. GIMS will play a pivotal role in providing solutions for validation and trials to many companies located in this park, further enhancing the ecosystem for medical technology startups in Uttar Pradesh. The main focus is to develop low-cost, high-quality healthcare technologies that can be adopted globally. Our goal is to create solutions that are affordable yet meet international standards, addressing both local and global healthcare needs. Our initiative, "Make in UP for the World," underscores our commitment to regional development while contributing to global healthcare advancements.   Anusha Ashwin ]]> https://biospectrumindia.com/news/110/24705/first-government-hospital-based-medical-incubation-centre-opens-in-greater-noida.html https://biospectrumindia.com/news/110/24705/first-government-hospital-based-medical-incubation-centre-opens-in-greater-noida.html Sat, 01 Jun 2024 00:00:00 +0530 First public hospital-based medical incubation centre in Uttar Pradesh has been officially opened at the Government Institute of Medical Sciences (GIMS), Greater Noida.  The inauguration of 'Centre for Medical Innovation-GIMS' was conducted on 01st June, by Chief Guest Dr Atul Goel, Director General of Health Services (DGHS) alongside Dr Chhaya Chauhan, Head of Incubation at BIRAC. In his address, DGHS emphasised the need to prevent diseases before it occur by implementing interventions. He interacted with all the startup founders and advised them to work on preventive diseases, rather than diagnostics and therapeutics. This centre is set to revolutionise healthcare innovation by providing a platform for medical startups and researchers to develop groundbreaking solutions. The mission is to foster collaboration and drive advancements that will transform patient care and the overall healthcare ecosystem. This Medical Incubation Centre has been developed in partnership with Stanford University’s Biodesign, ensuring cutting-edge innovation and collaboration. This incubator at GIMS will enhance accessibility to clinical mentoring, validation testing, and much more, driving medical innovation to new heights. GIMS has been recognised as the best Covid-19 care institute for treating the highest number of patients, excelling in research, and leading in innovation. ]]> https://biospectrumindia.com/news/110/24421/merck-life-science-enters-into-mou-with-amity-university-noida.html https://biospectrumindia.com/news/110/24421/merck-life-science-enters-into-mou-with-amity-university-noida.html Fri, 22 Mar 2024 00:00:00 +0530 Merck Life Science has announced the signing of a Memorandum of Understanding (MoU) with Amity University, Uttar Pradesh, Noida campus, envisioning significant collaborations between the organisation in Academics and Research.  Under this MoU, 'Practical & Industry Oriented Certificate Courses' focusing on advanced instrumentation will be offered to the students with hands-on training opportunities. The objective behind this collaboration is to ensure that the students are industry-ready.  The MoU was signed by Dhananjay Singh, Head, of Science and Lab Solutions, India Commercials from Merck Life Science, and Prof (Dr) R.K. Kapur and Dr W. Sevamurthy from the Amity University, Noida Campus, Uttar Pradesh.  Among the other dignitaries, Dr Pankaj Joshi, Head of Asia Pacific Commercial Marketing, Science and Lab Solutions APAC Commercials; Mahesh Goyal, Sales Head Academia (North and West) and Dr Paramita Sen, Ph.D., Solution Scientist from Merck were also present at the signing.  ]]> https://biospectrumindia.com/news/110/23975/uttar-pradeshs-first-ai-powered-advanced-state-of-the-art-cath-lab-launches-at-fortis-noida.html https://biospectrumindia.com/news/110/23975/uttar-pradeshs-first-ai-powered-advanced-state-of-the-art-cath-lab-launches-at-fortis-noida.html Tue, 19 Dec 2023 00:00:00 +0530 Fortis Hospital Noida has recently launched Uttar Pradesh’s First Artificial Intelligence (AI)-powered cath lab, a state-of-the-art facility designed for advanced and complex interventions in cardiac, neurology, and vascular procedures. This advanced cath lab is equipped with the AI version of GE Innova IGS 5, integrating high-end technologies to facilitate high precision-based interventional procedures, particularly for cardiac-related ailments. The high-resolution, 3D AI-based technology is adept at supporting complex angioplasties, structural heart procedures like TAVR, Mitra clip, and critical neuro interventions for stroke, along with other emergency vascular procedures. The advanced features of this cath lab are expected to reduce procedure times, enhance safety, and lead to improved clinical outcomes for patients. Dr Mohit Singh, Zonal Director, Fortis Hospital Noida said, “Non-communicable diseases (NCDs) are one of the major public health challenges, the irony is that majority of premature NCD deaths are preventable and artificial intelligence (AI) technologies have the potential to be a game-changer in this domain. Harnessing data and artificial intelligence to support clinical decisions has enormous potential to improve care for patients and efficiency. Using Artificial intelligence, doctors can use cutting-edge machine learning algorithms to anticipate the results of various interventions based on prior patient data, which will help aid precise medical interventions about the best medical course of action for the patient."  ]]>